Antikor Biopharma and Essex Bio-Technology forge strategic alliance in FDC for cancer treatment

This article was originally published here

Mahendra Deonarain, Antikor’s CEO and visiting Reader in Antibody Technology at Imperial College London where Antikor has its roots, commented: “We believe we have a platform that is

The post Antikor Biopharma and Essex Bio-Technology forge strategic alliance in FDC for cancer treatment appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply